Sign in

You're signed outSign in or to get full access.

Rebecca Liang

Senior Analyst at Sanford C. Bernstein & Co.

Rebecca Liang is a Senior Analyst at Sanford C. Bernstein & Co., specializing in research coverage of the China Pharma and Biotech sectors. She covers listed companies such as BeOne Medicines Ltd. and has issued ratings and research featured on platforms like Zacks, with her recommendations including a recent Hold rating on ONC. Rebecca joined Bernstein in 2020 after accumulating substantial industry and academic experience, reflected by her Ph.D. credentials. She is known for her deep sector expertise and likely holds relevant financial regulatory qualifications in the Hong Kong market.

Rebecca Liang's questions to Zai Lab (ZLAB) leadership

Question · Q1 2025

Rebecca Liang questioned if Zai Lab's R&D strategy is shifting more towards in-house development versus in-licensing, and asked about the expected impact of recent FDA leadership changes on the approval process for assets like ZL-1310.

Answer

Joshua Smiley, President and COO, and Dr. Rafael Amado, President and Head of Global R&D, clarified that the strategy remains a balance between internal discovery and external business development, with a goal of one new IND per year. Dr. Amado added that they have seen no impact from FDA changes and that ZL-1310's path via a randomized trial is viewed favorably.

Ask follow-up questions

Fintool

Fintool can predict Zai Lab logo ZLAB's earnings beat/miss a week before the call